News

U-Lace, FRAXA Partner to Help Fund Research for Fragile X Syndrome

During Autism Awareness Month in April, the nonprofit FRAXA Research Foundation and shoelace company U-Lace established a new partnership to help fund research for the treatment and cure of fragile X syndrome, the most common inherited cause of autism. The partnership will begin with special marketing programs and the development of custom,…

FDA Grants Orphan Drug Status to Investigational Therapy BPN14770 for Fragile X Syndrome

Investigational therapy BPN14770 has received orphan drug status from the U.S. Food and Drug Administration as a treatment for fragile X syndrome, Tetra Discovery Partners recently announced. BPN14770, a small molecule therapeutic agent developed by Tetra Discovery, inhibits the phosphodiesterase type-4D (PDE4D) enzyme linked to memory formation and learning…